175 related articles for article (PubMed ID: 1607582)
1. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators.
Akiyama T; Pawitan Y; Campbell WB; Papa L; Barker AH; Rubbert P; Friedman L; Keller M; Josephson RA
J Am Geriatr Soc; 1992 Jul; 40(7):666-72. PubMed ID: 1607582
[TBL] [Abstract][Full Text] [Related]
2. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST).
Anderson JL; Platia EV; Hallstrom A; Henthorn RW; Buckingham TA; Carlson MD; Carson PE
Circulation; 1994 Dec; 90(6):2843-52. PubMed ID: 7994829
[TBL] [Abstract][Full Text] [Related]
3. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
Cardiac Arrhythmia Pilot Study (CAPS) Investigators
Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
Akiyama T; Pawitan Y; Greenberg H; Kuo CS; Reynolds-Haertle RA
Am J Cardiol; 1991 Dec; 68(17):1551-5. PubMed ID: 1720917
[TBL] [Abstract][Full Text] [Related]
5. Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy.
Bigger JT; Rolnitzky LM; Steinman RC; Fleiss JL
J Am Coll Cardiol; 1994 Mar; 23(3):733-40. PubMed ID: 7509355
[TBL] [Abstract][Full Text] [Related]
6. Treatment of ventricular arrhythmias after CAST.
Tonkin AM
Med J Aust; 1992 Apr; 156(7):488-92. PubMed ID: 1372950
[TBL] [Abstract][Full Text] [Related]
7. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Cardiac Arrhythmia Suppression Trial (CAST) Investigators
N Engl J Med; 1989 Aug; 321(6):406-12. PubMed ID: 2473403
[TBL] [Abstract][Full Text] [Related]
8. The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II.
Greene HL; Roden DM; Katz RJ; Woosley RL; Salerno DM; Henthorn RW
J Am Coll Cardiol; 1992 Apr; 19(5):894-8. PubMed ID: 1552108
[TBL] [Abstract][Full Text] [Related]
9. Association between ease of suppression of ventricular arrhythmia and survival.
Goldstein S; Brooks MM; Ledingham R; Kennedy HL; Epstein AE; Pawitan Y; Bigger JT
Circulation; 1995 Jan; 91(1):79-83. PubMed ID: 7805221
[TBL] [Abstract][Full Text] [Related]
10. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
Bigger JT
Am J Cardiol; 1990 Feb; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253
[TBL] [Abstract][Full Text] [Related]
11. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST).
Epstein AE; Hallstrom AP; Rogers WJ; Liebson PR; Seals AA; Anderson JL; Cohen JD; Capone RJ; Wyse DG
JAMA; 1993 Nov; 270(20):2451-5. PubMed ID: 8230622
[TBL] [Abstract][Full Text] [Related]
12. Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients.
Capone RJ; Pawitan Y; el-Sherif N; Geraci TS; Handshaw K; Morganroth J; Schlant RC; Waldo AL
J Am Coll Cardiol; 1991 Nov; 18(6):1434-8. PubMed ID: 1939943
[TBL] [Abstract][Full Text] [Related]
13. Relation of baseline characteristics to suppression of ventricular arrhythmias during placebo and active antiarrhythmic therapy in patients after myocardial infarction.
Anderson JL; Hallstrom AP; Griffith LS; Ledingham RB; Reiffel JA; Yusuf S; Barker AH; Fowles RE; Young JB
Circulation; 1989 Mar; 79(3):610-9. PubMed ID: 2465099
[TBL] [Abstract][Full Text] [Related]
14. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in patients surviving open label titration but not randomized to double-blind therapy.
Wyse DG; Hallstrom A; McBride R; Cohen JD; Steinberg JS; Mahmarian J
J Am Coll Cardiol; 1991 Jul; 18(1):20-8. PubMed ID: 1904892
[TBL] [Abstract][Full Text] [Related]
15. Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial.
Hallstrom AP; Anderson JL; Carlson M; Davies R; Greene HL; Kammerling JM; Romhilt DW; Duff HJ; Huther M
Am Heart J; 1995 Jul; 130(1):71-9. PubMed ID: 7611126
[TBL] [Abstract][Full Text] [Related]
16. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST).
Peters RW; Mitchell LB; Brooks MM; Echt DS; Barker AH; Capone R; Liebson PR; Greene HL
J Am Coll Cardiol; 1994 Feb; 23(2):283-9. PubMed ID: 8294678
[TBL] [Abstract][Full Text] [Related]
17. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled.
Epstein AE; Bigger JT; Wyse DG; Romhilt DW; Reynolds-Haertle RA; Hallstrom AP
J Am Coll Cardiol; 1991 Jul; 18(1):14-9. PubMed ID: 1904891
[TBL] [Abstract][Full Text] [Related]
18. Recruitment and baseline description of patients in the Cardiac Arrhythmia Pilot Study. The Cardiac Arrhythmia Pilot Study (CAPS) investigators.
Am J Cardiol; 1988 Apr; 61(10):704-13. PubMed ID: 2451414
[TBL] [Abstract][Full Text] [Related]
19. Crime, misdemeanor, and arrhythmia decoding CAST.
Kerin NZ
J Clin Pharmacol; 1991 Nov; 31(11):1044-52. PubMed ID: 1753008
[No Abstract] [Full Text] [Related]
20. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial.
Hallstrom A; Pratt CM; Greene HL; Huther M; Gottlieb S; DeMaria A; Young JB
J Am Coll Cardiol; 1995 May; 25(6):1250-7. PubMed ID: 7722117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
